New drug may keep High-Risk NETs from coming back after surgery
NCT ID NCT07279532
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests whether the drug surufatinib can help prevent neuroendocrine tumors (NETs) from returning after surgery. It enrolls 35 adults with stage III NETs who are at high risk of recurrence. Participants will take surufatinib after their operation, and researchers will track how long they stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS (TUMOURS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.